Is Regorafenib included in medical insurance?

Regorafenib(Regorafenib) is a class of anti-tumor drugs that are oral tumor inactivators that can effectively block a variety of protein kinases, including those involved in tumor angiogenesis< /span>Kases for (VEGFR1, -2, -3, TIE2), tumorigenesis (KIT, RET, RAF-1, BRAF, BRAFV600E), metastasis (VEGFR3, PDGFR, FGFR) and tumor immunity (CSF1R). Regofenibreduces the levels of tumor-associated macrophages and displays antimetastatic effects in vivo. The major human metabolites (M-2 and M-5) exhibit similar efficacy to regorafenib in in vitro and in vivo models.

Inhibits mutatedKIT, the major oncogenic driver in gastrointestinal stromal tumors, thereby blocking tumor cell proliferation. In preclinical studies, regorafenib demonstrated potent anti-tumor activity in a broad spectrum of tumor models, including colorectal, gastrointestinal stromal and hepatocellular tumor models, which may be mediated by its anti-angiogenic and anti-proliferative effects.

RegofenibThe original drug has been launched in China and has entered the scope of Class B medical insurance. Reimbursement is limited to patients who meet the indications. SpecificationThe price of each box of 40mg*28 tablets is around RMB 5,000. The reimbursement ratio is different in different regions, and the price after reimbursement is different. The Turkish version of regorafeniboriginal drug specifications 40mg*28 tablets sold overseas is priced around RMB 6,400 per box (the price may fluctuate due to exchange rates). There are also generic regorafenib drugs produced in other countries, and their drug ingredients are basically the same as those of the original drug. The price of a box of 40mg*90 tablets produced by a Bangladesh pharmaceutical factory is around 2,900 yuan (the price may fluctuate due to exchange rates).